UY33487A - ?(3-(4-(aminometil)fenoxi o feniltio)azetidin-1-il)(5-fenil-1,3,4-oxadiazol- 2-il)metanona?. - Google Patents
?(3-(4-(aminometil)fenoxi o feniltio)azetidin-1-il)(5-fenil-1,3,4-oxadiazol- 2-il)metanona?.Info
- Publication number
- UY33487A UY33487A UY0001033487A UY33487A UY33487A UY 33487 A UY33487 A UY 33487A UY 0001033487 A UY0001033487 A UY 0001033487A UY 33487 A UY33487 A UY 33487A UY 33487 A UY33487 A UY 33487A
- Authority
- UY
- Uruguay
- Prior art keywords
- azetidin
- methanone
- oxadiazol
- phenylthio
- aminomethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
En la presente se describen compuestos azetidinílicos de fórmula I, como los descritos en la presente, composiciones farmacéuticas que comprenden un compuesto azetidinílico y un método para utilizar un compuesto azetidinílico en el tratamiento o la profilaxis de una enfermedad o afección relacionada con una hormona concentradora de melanina.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36158510P | 2010-07-06 | 2010-07-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY33487A true UY33487A (es) | 2012-02-29 |
Family
ID=44514822
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001033487A UY33487A (es) | 2010-07-06 | 2011-07-06 | ?(3-(4-(aminometil)fenoxi o feniltio)azetidin-1-il)(5-fenil-1,3,4-oxadiazol- 2-il)metanona?. |
Country Status (26)
Country | Link |
---|---|
US (1) | US8546375B2 (es) |
EP (1) | EP2590969B1 (es) |
JP (1) | JP5827683B2 (es) |
KR (1) | KR20130041177A (es) |
CN (1) | CN103209979B (es) |
AR (1) | AR082113A1 (es) |
AU (1) | AU2011275547B2 (es) |
BR (1) | BR112013000296A2 (es) |
CA (1) | CA2802832A1 (es) |
CL (1) | CL2013000027A1 (es) |
CR (1) | CR20130005A (es) |
CU (1) | CU20130004A7 (es) |
DO (1) | DOP2013000004A (es) |
EA (1) | EA201291384A1 (es) |
EC (1) | ECSP13012369A (es) |
ES (1) | ES2527466T3 (es) |
GT (1) | GT201300006A (es) |
HK (1) | HK1182712A1 (es) |
MX (1) | MX2012015102A (es) |
NI (1) | NI201200196A (es) |
PE (1) | PE20130781A1 (es) |
SA (1) | SA111320581B1 (es) |
SG (1) | SG186275A1 (es) |
TW (1) | TW201206916A (es) |
UY (1) | UY33487A (es) |
WO (1) | WO2012004588A2 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY34194A (es) | 2011-07-15 | 2013-02-28 | Astrazeneca Ab | ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad? |
CN104974106B (zh) * | 2014-04-04 | 2019-02-22 | 浙江普洛康裕制药有限公司 | 5-烷基-[1,3,4]-噁二唑-2-甲酸烷基酯的合成方法 |
CN108840812B (zh) * | 2018-06-29 | 2020-08-18 | 南京富润凯德生物医药有限公司 | 一种3-(二氟甲基)-3-羟基氮杂环丁烷中间体及其盐的制备方法 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4212867A (en) * | 1977-03-03 | 1980-07-15 | Philagro | 2-Cyano-5-substituted 1,3,4-oxadiazoles and fungicidal compositions containing them |
DE3039087A1 (de) | 1980-10-16 | 1982-05-19 | Hoechst Ag, 6000 Frankfurt | 1-(1,3-dioxolan-2-ylmethyl)-azole, ihre salze, verfahren zu ihrer herstellung und ihre verwendung |
CA1247547A (en) | 1983-06-22 | 1988-12-28 | Paul Hadvary | Leucine derivatives |
GB2184122B (en) | 1985-12-17 | 1989-10-18 | Boots Co Plc | N,n-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methyl butylamine hydrochloride monohydrate |
GB8531071D0 (en) | 1985-12-17 | 1986-01-29 | Boots Co Plc | Therapeutic compound |
EP0619814A1 (en) | 1991-12-31 | 1994-10-19 | Fujisawa Pharmaceutical Co., Ltd. | Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity |
AU6788996A (en) | 1995-08-02 | 1997-02-26 | J. Uriach & Cia S.A. | New carboxamides with antifungal activity |
SE0202134D0 (sv) | 2002-07-08 | 2002-07-08 | Astrazeneca Ab | Therapeutic agents |
US7541477B2 (en) | 2002-07-30 | 2009-06-02 | Banyu Pharmaceutical Co., Ltd. | Antagonists to melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient |
WO2004072018A1 (ja) | 2003-02-12 | 2004-08-26 | Takeda Pharmaceutical Company Limited | アミン誘導体 |
US20060293298A1 (en) | 2003-04-10 | 2006-12-28 | Bamford Mark J | Compounds |
US20070185079A1 (en) | 2004-01-07 | 2007-08-09 | Astrazeneca Ab | Therapeutic agents I |
GB0400193D0 (en) | 2004-01-07 | 2004-02-11 | Astrazeneca Ab | Therapeutic agents |
US7241787B2 (en) | 2004-01-25 | 2007-07-10 | Sanofi-Aventis Deutschland Gmbh | Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments |
TW200538098A (en) | 2004-03-22 | 2005-12-01 | Astrazeneca Ab | Therapeutic agents |
CN1989115B (zh) | 2004-07-26 | 2012-03-21 | 伊莱利利公司 | 作为组胺h3受体药物的噁唑衍生物及其制备和制药用途 |
ES2318565T3 (es) | 2004-10-18 | 2009-05-01 | Eli Lilly And Company | Inhibidores del receptor de la histamina h3, su preparacion y sus usos terapeuticos. |
PL1828177T3 (pl) | 2004-12-17 | 2009-01-30 | Lilly Co Eli | Nowi antagoniści receptora MCH |
AR051802A1 (es) | 2004-12-21 | 2007-02-07 | Astrazeneca Ab | Heterociclos antagonistas de mchr1 |
JP2006176443A (ja) | 2004-12-22 | 2006-07-06 | Shionogi & Co Ltd | メラニン凝集ホルモン受容体アンタゴニスト |
CN101184753A (zh) | 2005-05-31 | 2008-05-21 | 阿斯利康(瑞典)有限公司 | 新颖的mchr1拮抗剂以及它们用于治疗mchr1介导的病症和疾病的用途 |
US7709516B2 (en) | 2005-06-17 | 2010-05-04 | Endorecherche, Inc. | Helix 12 directed non-steroidal antiandrogens |
US7812040B2 (en) | 2005-06-22 | 2010-10-12 | Pfizer Inc. | Histamine-3 receptor antagonists |
EP1907398A1 (en) | 2005-07-15 | 2008-04-09 | AstraZeneca AB | Therapeutic agents |
UY30079A1 (es) | 2006-01-06 | 2007-08-31 | Astrazeneca Ab | Compuestos |
EP2051977A2 (en) | 2006-07-20 | 2009-04-29 | Amgen Inc. | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLbeta-HSD-1 |
JP2010501553A (ja) | 2006-08-18 | 2010-01-21 | アストラゼネカ アクチボラグ | Mchr1アンタゴニストとしてのチエノピリミジン−4−オン誘導体およびチエノピリダジン−7−オン誘導体 |
MX2009005908A (es) | 2006-12-05 | 2009-06-16 | Janssen Pharmaceutica Nv | Derivados novedosos de diaza-espiro-piridinona sustituidos para usarse en las enfermedades mediadas por la hormona concentradora de melanina 1. |
BRPI0721086A2 (pt) * | 2006-12-14 | 2014-02-25 | Lilly Co Eli | Derivados de 5-[4-(azetidin-3-ilóxi)-fenil]-2-fenil-5h-tiazolo[5,4-c]piri din-4-ona e seu emprego como antago-nistas de receptor de mch |
WO2008131103A2 (en) | 2007-04-17 | 2008-10-30 | Vertex Pharmaceuticals Incorporated | Drug discovery methods for aurora kinase inhibitors |
WO2009018415A1 (en) | 2007-07-31 | 2009-02-05 | Vertex Pharmaceuticals Incorporated | Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof |
EP2190815B1 (en) | 2007-08-22 | 2011-08-10 | F. Hoffmann-La Roche AG | Pyrrolidine aryl-ether as nk3 receptor antagonists |
MX2010003949A (es) * | 2007-10-17 | 2010-04-30 | Sanofi Aventis | N-fenil-bipirrolidina carboxamidas sustituidas y uso terapeutico de las mismas. |
US8124636B2 (en) | 2008-04-30 | 2012-02-28 | Hoffmann-La Roche Inc. | Imidazolidinone derivatives as 11B-HSD1 inhibitors |
CA2721303C (en) * | 2008-05-08 | 2016-06-28 | Evotec Ag | Azetidines and cyclobutanes as histamine h3 receptor antagonists |
SA110310332B1 (ar) * | 2009-05-01 | 2013-12-10 | Astrazeneca Ab | مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل ) |
WO2011019090A1 (en) | 2009-08-13 | 2011-02-17 | Mitsubishi Tanabe Pharma Corporation | Pyrimidone derivatives used as tau protein kinase 1 inhibitors |
WO2011058766A1 (en) * | 2009-11-16 | 2011-05-19 | Raqualia Pharma Inc. | Aryl carboxamide derivatives as ttx-s blockers |
-
2011
- 2011-07-04 EP EP11729458.7A patent/EP2590969B1/en active Active
- 2011-07-04 MX MX2012015102A patent/MX2012015102A/es active IP Right Grant
- 2011-07-04 JP JP2013517542A patent/JP5827683B2/ja not_active Expired - Fee Related
- 2011-07-04 WO PCT/GB2011/051256 patent/WO2012004588A2/en active Application Filing
- 2011-07-04 KR KR1020137003150A patent/KR20130041177A/ko not_active Application Discontinuation
- 2011-07-04 AU AU2011275547A patent/AU2011275547B2/en not_active Ceased
- 2011-07-04 BR BR112013000296A patent/BR112013000296A2/pt not_active IP Right Cessation
- 2011-07-04 CN CN201180042363.6A patent/CN103209979B/zh not_active Expired - Fee Related
- 2011-07-04 ES ES11729458.7T patent/ES2527466T3/es active Active
- 2011-07-04 PE PE2013000016A patent/PE20130781A1/es not_active Application Discontinuation
- 2011-07-04 CA CA2802832A patent/CA2802832A1/en not_active Abandoned
- 2011-07-04 SA SA111320581A patent/SA111320581B1/ar unknown
- 2011-07-04 EA EA201291384A patent/EA201291384A1/ru unknown
- 2011-07-04 SG SG2012090882A patent/SG186275A1/en unknown
- 2011-07-05 TW TW100123724A patent/TW201206916A/zh unknown
- 2011-07-05 US US13/176,554 patent/US8546375B2/en not_active Expired - Fee Related
- 2011-07-05 AR ARP110102401A patent/AR082113A1/es not_active Application Discontinuation
- 2011-07-06 UY UY0001033487A patent/UY33487A/es not_active Application Discontinuation
-
2012
- 2012-12-28 NI NI201200196A patent/NI201200196A/es unknown
-
2013
- 2013-01-03 CL CL2013000027A patent/CL2013000027A1/es unknown
- 2013-01-04 DO DO2013000004A patent/DOP2013000004A/es unknown
- 2013-01-04 EC ECSP13012369 patent/ECSP13012369A/es unknown
- 2013-01-04 GT GT201300006A patent/GT201300006A/es unknown
- 2013-01-04 CU CU2013000004A patent/CU20130004A7/es unknown
- 2013-01-07 CR CR20130005A patent/CR20130005A/es unknown
- 2013-08-30 HK HK13110163.5A patent/HK1182712A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AR082113A1 (es) | 2012-11-14 |
AU2011275547B2 (en) | 2015-10-29 |
ES2527466T3 (es) | 2015-01-26 |
NI201200196A (es) | 2013-10-16 |
ECSP13012369A (es) | 2013-01-31 |
KR20130041177A (ko) | 2013-04-24 |
SA111320581B1 (ar) | 2014-06-17 |
EA201291384A1 (ru) | 2013-07-30 |
MX2012015102A (es) | 2013-05-01 |
CN103209979B (zh) | 2016-02-10 |
GT201300006A (es) | 2014-11-06 |
WO2012004588A3 (en) | 2012-08-09 |
JP2013535413A (ja) | 2013-09-12 |
WO2012004588A2 (en) | 2012-01-12 |
EP2590969B1 (en) | 2014-10-15 |
CU20130004A7 (es) | 2013-05-31 |
SG186275A1 (en) | 2013-01-30 |
BR112013000296A2 (pt) | 2019-09-24 |
CR20130005A (es) | 2013-04-17 |
US8546375B2 (en) | 2013-10-01 |
JP5827683B2 (ja) | 2015-12-02 |
EP2590969A2 (en) | 2013-05-15 |
PE20130781A1 (es) | 2013-07-20 |
US20120010189A1 (en) | 2012-01-12 |
CA2802832A1 (en) | 2012-01-12 |
CL2013000027A1 (es) | 2013-03-08 |
TW201206916A (en) | 2012-02-16 |
AU2011275547A1 (en) | 2013-02-07 |
DOP2013000004A (es) | 2013-04-30 |
CN103209979A (zh) | 2013-07-17 |
HK1182712A1 (en) | 2013-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR117613A2 (es) | Combinación farmacéutica | |
ECSP088747A (es) | Pirazoles como inhibidores de la 11-beta-hsd1 | |
CU20140068A7 (es) | Triazolopiridinas sustituidas | |
BR112012023021A2 (pt) | compostos de indazol e seus usos | |
CU20120171A7 (es) | Triazolopiridinas sustituidas | |
EA201690102A1 (ru) | Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе | |
EA201491060A1 (ru) | Новые производные трифторметилоксадиазола и их применение для лечения заболевания | |
UY30809A1 (es) | Derivados de n-[3-[4-fenil)piperidin-1-carbonil]fenil]sulfonamidas sustituidas, procesos de preparacion y aplicaciones | |
AR079890A1 (es) | Estabilizacion de peliculas de oxido de zinc en composiciones bucales | |
ECSP10010106A (es) | Trans-clomifeno para el síndrome metabólico | |
ECSP13013012A (es) | Análogos del ácido epoxieicosatrienoicos y métodos de preparación | |
CL2011000258A1 (es) | Compuestos derivados de fenilamino-isonicotinamida; inhibidores de mek; composicion farmaceutica y uso para el tratamiento de enfermedades hiperproliferativas tales como cancer e inflamacion. | |
EP4327886A3 (en) | Pyrimido- pyridazinone compounds and use thereof | |
BR112014020113A8 (pt) | Composições farmacêuticas e método para diminuir a frequência de micção | |
PE20142399A1 (es) | Compuestos de pirazol como inhibidores de sglt1 | |
MX367926B (es) | Composicion farmaceutica para liberacion sostenida de lanreotida. | |
BR122020011180B8 (pt) | formulações injetáveis de compostos de tetraciclina | |
AR095032A1 (es) | Formulaciones de compuestos orgánicos, composición farmacéutica sólida comprimida por rodillo | |
UY33487A (es) | ?(3-(4-(aminometil)fenoxi o feniltio)azetidin-1-il)(5-fenil-1,3,4-oxadiazol- 2-il)metanona?. | |
CL2011001829A1 (es) | 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo. | |
CL2011003123A1 (es) | Compuestos derivados de ciclopentanamida sustituidos; composicion farmaceutica; proceso de obtencion; y uso en el tratamiento o la profilaxis de la diabetes, aterosclerosis, entre otras. | |
PE20130308A1 (es) | Metodos para tratar infecciones bacterianas recurrentes | |
BR112016011932A2 (pt) | Composições clareadoras para cuidado oral contendo compostos graxos anfifílicos | |
BR112014000485A2 (pt) | derivados de azetidina para o tratamento de transtornos relacionados à melanina | |
CL2012001203A1 (es) | Compuestos derivados de 4-aminociclohexano modulares del receptor arl1; proceso para la preparacion de los compuestos; medicamento que comprende uno de los compuestos; y uso de los componpuestos en la preparacion de medicamentos para el tratamiento del dolor, en especial el dolor neuropatico. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20200807 |